Medpace (NASDAQ:MEDP) Upgraded at StockNews.com

StockNews.com upgraded shares of Medpace (NASDAQ:MEDP) from a hold rating to a buy rating in a research note released on Tuesday.

Other equities research analysts have also issued research reports about the stock. TD Cowen began coverage on shares of Medpace in a research note on Wednesday, May 29th. They issued a buy rating and a $452.00 target price on the stock. Robert W. Baird upped their target price on shares of Medpace from $456.00 to $469.00 and gave the company an outperform rating in a research note on Monday, July 8th. Mizuho began coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a buy rating and a $435.00 target price on the stock. Guggenheim upped their target price on shares of Medpace from $453.00 to $464.00 and gave the company a buy rating in a research note on Wednesday, April 24th. Finally, Jefferies Financial Group upgraded shares of Medpace from a hold rating to a buy rating and upped their target price for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $424.14.

Medpace Trading Down 0.4 %

Shares of Medpace stock opened at $380.50 on Tuesday. Medpace has a twelve month low of $227.21 and a twelve month high of $459.77. The stock has a market cap of $11.79 billion, a price-to-earnings ratio of 38.79, a price-to-earnings-growth ratio of 1.76 and a beta of 1.36. The company has a fifty day moving average price of $404.55 and a 200 day moving average price of $381.65.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 59.91%. The firm had revenue of $528.10 million for the quarter, compared to analyst estimates of $528.41 million. During the same quarter in the previous year, the business posted $1.93 EPS. The firm’s revenue was up 14.6% compared to the same quarter last year. Analysts forecast that Medpace will post 11.33 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO August J. Troendle sold 15,102 shares of the stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the sale, the chief executive officer now owns 791,541 shares in the company, valued at $317,162,563.29. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Medpace news, CEO August J. Troendle sold 3,987 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $395.22, for a total value of $1,575,742.14. Following the completion of the transaction, the chief executive officer now owns 660,351 shares in the company, valued at approximately $260,983,922.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 15,102 shares of the company’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The disclosure for this sale can be found here. Insiders have sold a total of 29,621 shares of company stock worth $11,816,852 over the last quarter. 20.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Arcadia Investment Management Corp MI grew its position in Medpace by 40.3% in the 1st quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 29 shares during the last quarter. Miller Howard Investments Inc. NY boosted its holdings in shares of Medpace by 1.3% in the fourth quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after acquiring an additional 39 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Medpace by 5.3% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock valued at $316,000 after acquiring an additional 39 shares in the last quarter. Coldstream Capital Management Inc. boosted its holdings in shares of Medpace by 5.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock valued at $292,000 after acquiring an additional 45 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Medpace by 43.3% in the first quarter. GAMMA Investing LLC now owns 149 shares of the company’s stock valued at $60,000 after acquiring an additional 45 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.